Natixis Advisors LLC Sells 11,071 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Natixis Advisors LLC cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 2.4% in the 3rd quarter, Holdings Channel reports. The fund owned 457,040 shares of the company’s stock after selling 11,071 shares during the quarter. Natixis Advisors LLC’s holdings in Takeda Pharmaceutical were worth $6,499,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the last quarter. Headlands Technologies LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Hexagon Capital Partners LLC boosted its stake in Takeda Pharmaceutical by 34.3% in the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after buying an additional 1,129 shares in the last quarter. Blue Trust Inc. grew its position in Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after acquiring an additional 2,330 shares during the last quarter. Finally, Ridgewood Investments LLC purchased a new position in shares of Takeda Pharmaceutical during the second quarter worth approximately $89,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.4 %

Shares of TAK opened at $13.38 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The firm has a 50 day moving average price of $14.10 and a 200-day moving average price of $13.83. The firm has a market cap of $42.57 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.